NCT05094570View on ClinicalTrials.gov

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Nasal PolypsStaphylococcus Aureus

Interventions

DRUG

Dupilumab Prefilled Syringe

Dupilumab 300 mg

Trial Locations (1)

22908

RECRUITING

University of Virginia Health System, Charlottesville

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of Virginia

OTHER

NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP | Biotech Hunter | Biotech Hunter